ALK Positive Lung Cancer UK
@alkpositiveuk.bsky.social
💙 Supporting, empowering & advocating for those with ALK+ lung cancer in the UK 🧬 Advocacy | Awareness | Trusted resources 🫶 NICE-recognised, improving lives, driving change, and amplifying our community voices linktr.ee/alkpositivelungcanceruk
When ALK+ #lungcancer progresses, there can be a lot to take in & important decisions to discuss. Our 🆕 Talking Points resource is designed to support those conversations, with practical questions people may want to discuss with their healthcare team. www.alkpositive.org.uk/our-publicat... #LCSM
Our clinical director Charlie Swanton spoke to James Gallagher on Inside Health this morning about his team's work investigating the biological processes that link inflammation and lung cancer. Catch up on BBC Sounds from 5:35 https://www.bbc.co.uk/sounds/play/m002zggr
Inside Health - Is inflammation behind all chronic disease? - BBC Sounds
How understanding inflammation could transform treatments from cancer to Alzheimer’s.
bbc.co.uk
Why Britain is breathing the world’s wildfire smoke Scientists say global blazes account for 10% of UK’s particle pollution – and climate crisis could make the problem worse #AirPollution #Wildfires #WildfireSmoke www.theguardian.com/environment/... by @drgaryfuller.bsky.social
Why Britain is breathing the world’s wildfire smoke
Scientists say global blazes account for 10% of UK’s particle pollution – and climate crisis could make the problem worse
theguardian.com
Wales’ new 10-yr cancer strategy must recognise that #lungcancer is not one disease. For people with ALK+, that means faster diagnosis, comprehensive biomarker testing, equal access to specialist care & targeted treatments, & research into drug resistance & brain mets. #LCSM
What draws an oncologist to work in ALK+ #lungcancer? Dr Tom Newsom-Davis, who is the keynote speaker for our 5th National Conference this September shares his thoughts. He speaks about the impact of seeing people do well - often year after year, & how incredibly rewarding that is. #LCSM
19 yrs ago today, a Japanese research team led by Dr Hiroyuki Mano published the 1st paper describing the ALK rearrangement in #lungcancer. That discovery changed the future of ALK+, paving the way for targeted treatments that have transformed care & helped many people live longer & better. #LCSM
1 August is #WorldLungCancerDay. Imagine being 28, a cough that won’t go, & you’ve never smoked. Nobody investigates & by the time it’s found it’s stage 4. 65% of people with #lungcancer delay seeking help*, often due to age or smoking status. Push for answers. *Source: Lung Cancer Europe #LCSM
Changes in mood, thinking and behaviour associated with ALK+ #lungcancer inhibitors, particularly lorlatinib, remain an important aspect of treatment that deserves greater awareness. Our website Treatments section provides an overview of the available ALK inhibitors and practical resources. #LCSM
Current ambitions to improve health and reduce inequalities risk falling short if we continue to overlook the role of preconception health. Veena Raleigh explores why improving preconception health must become a much bigger public health priority. Read the blog: https://bit.ly/4yF4gtt
8 yrs ago we had our 1st meet-up which was the start of ALK+ #LungCancer UK’s journey! 💙 In 2018, with no ALK+ UK support groups, Debra, our Chair, reached out to fellow UK patients on a US forum. There were 18 at the meet-up & we were incredibly fortunate to have Prof Sanjay Popat join us. #LCSM
Which is the world’s biggest cancer killer? The latest WHO Global Status Report on Cancer shows lung cancer remained the leading cause of cancer death worldwide in 2024. Read our 9 key takeaways. 🔗 lungcancereurope.eu/news/9-takea... #LungCancer #LCSM
New in NEJM: The Phase III ELEVATE trial found that adjuvant ensartinib significantly improved disease-free survival after surgery for ALK-positive #lungcancer. Another reminder that biomarker testing is increasingly important in early-stage lung cancer too. www.nejm.org/doi/full/10.... #LCSM
New from ALK+ UK: Talking Points - a practical guide to help people with ALK-positive #lungcancer prepare for conversations with their healthcare team. It also carries the PIF TICK for trusted health information. Read and download 🔗 tr.ee/sfj70T0tHU #LCSM
The Brenda Cobb Hardship Fund offers grants of up to £500 to help people affected by ALK+ #lungcancer facing financial hardship. It can also help with private NGS in some cases. A sincere 🙏 to Brenda’s som Callum for creating this fund Find out more: www.alkpositive.org.uk/hardship-fun... #LCSM
📣 The July NLCA Newsletter is here! 👉 Read it here: www.natcan.org.uk/news/nlca-ne... @hqip.bsky.social @btog.bsky.social @lcnuk.bsky.social @natcan-news.bsky.social
NLCA Newsletter, July 2026 - National Cancer Audit Collaborating Centre
natcan.org.uk
'England lost public health from the NHS in 2013 through misjudgement and poor specification. The next generation of NHS architecture is being designed now. We don't have to make the same mistake again.' Guest blog authors, Joe Home, Joe Dallaz and Frances Burnett Read more: https://bit.ly/3SQPjnu
Researchers at the University of Glasgow have launched the SWIFT-Lung study to investigate whether AI could help identify lung nodules more quickly and consistently. The technology is designed to support clinical teams, with the aim of improving #lungcancer diagnosis and patient care. #LCSM
Prof Alastair Greystoke, Thoracic Consultant at Newcastle Cancer Centre, is our new Honorary Clinical Advisor. Here he talks through the developments he is watching closely in ALK+ #lungcancer: new tablets, new drug classes, and approaches that use the immune system in more targeted ways. #LCSM
Our new guide, Talking Points, has been created to help people with ALK+ #lungcancer ask useful questions during appointments with their healthcare team. It covers treatment decisions, QOL, scans, ECGs, bone mets, blood clots, side effects, supportive, palliative care, & more! #LCSM
Leptomeningeal disease is an uncommon but serious problem in ALK+ #lungcancer. At #ASCO26, the largest study found people given lorlatinib after diagnosis lived far longer than those on a 2nd-gen TKI like alectinib or brigatinib (32.6 vs 7 months). Retrospective, no UK data. shorturl.at/nVw1V #LCSM
This week is Carers Week (8-14 June). 1 in 4 #lungcancer carers in the UK rarely or never talk about how they’re feeling. That’s one of the findings from a Lung Cancer Europe survey that our community took part in. Supporting someone you love through a lung cancer diagnosis is hard. #LCSM
Healthy cooperation: how northern universities are linking with NHS trusts to drive innovation
Healthy cooperation: how northern universities are linking with NHS trusts to drive innovation
Backed by a mix of private and public finance, Huddersfield and Manchester are among many in the academic sector helping to create jobs and growth
theguardian.com
#CCR26 begins! 3 days of practice-changing clinical trial results, all from sunny Belfast! Join us at the foot of the famous titanic steps, or online at https://criticalcarereviews.com/
Home
The most up-to-date critical care website in the world
criticalcarereviews.com
🙌 It’s Volunteers’ Week and we want to say a big thank you to everyone who gives their time so generously to volunteer for ALK+ UK and help us better support our ALK+ #lungcancer community. If would like to help us or just find out more, email hello@alkpositive.org.uk. #LCSM
New at #ASCO26: the LORIN trial tested lorlatinib before surgery in stage III ALK+ #lungcancer. 75% of those initially considered inoperable went on to have surgery. pCR 47%, MPR 81%, 1-year EFS 97%. Early data, but notable results. #LCSM ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.8002
🔥ASCO Living Guideline update: Stage IV NSCLC with driver alterations 2026.3.1 🆙 Journal of Clinical Oncology ☑Latest update incorporating new evidence for targeted therapies 🎙Dr. Joshua Reuss / Dr. Sonam Puri #LCSM @oncoalert.bsky.social @ascocancer.bsky.social
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.1
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular…
doi.org
‼️ #ASCO26 simultaneous publication by Trosman et al: Optimizing Cancer Care Delivery Through High-Functioning Teams: Results of Implementing the 4R Oncology Model in Lung and Breast Cancer Read the full article: https://bit.ly/4v6hwoa #lcsm #bcsm
After lorlatinib, what comes next for ALK+ #lungcancer? New ASCO 2026 data on neladalkib - the Nuvalent trial - shows 31% response in heavily pre-treated patients, rising to 46% without prior lorlatinib. Early data, not yet approved. But a real signal. Abstract 8503 #ASCO26 #LCSM
🔥ASCO Living Guideline update: Stage IV NSCLC without driver alterations 2026.3.1 🆙 @JCO_ASCO ☑Latest update incorporating new evidence for ICI-based regimens in NSCLC 🎙Dr. Lyudmila Bazhenova @hhorinouchi.bsky.social #LCSM @oncoalert.bsky.social @ascocancer.bsky.social doi.org/10.1200/JCO-...
